Multiple myeloma is a type of cancer where plasma cells ... Hypercalcemia can also impair kidney function. The early stages of kidney disease often don’t cause symptoms, but your doctor might ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...
The Jefferson County Senior Services Division is hosting The MMRF Multiple Myeloma Community Connect event on Thursday, Nov.
Johnson & Johnson’s CD38 inhibitor Darzalex showed a benefit in delaying or preventing disease progression in patients with ...
Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...
Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between IRF4 ...
Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 ...
Nammi Therapeutics begins patient dosing in phase 1 study of QXL138AM for advanced solid tumours and multiple myeloma: Los Angeles Monday, November 11, 2024, 13:00 Hrs [IST] Nammi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback